Updated Canadian Rheumatology Association (CRA) Position Statement on Biosimilars

From the Canadian Rheumatology Association (May 21, 2019):

As evidence for the benefits and risks of using biosimilars in the management of rheumatic diseases has grown rapidly, the Canadian Rheumatology Association (CRA) has updated its position statement on biosimilars accordingly. We have undertaken this initiative to ensure that you and your patients are in possession of up-to-date guidance regarding the use and potential benefits and risks of biosimilars so that informed and appropriate treatment decisions may be made.

Please click here to view the updated position statement and FAQ’s.

Note that the CIBRN Leaders will be discussing this updated position policy at the CIBRN webinar to be held Wednesday, May 21 2019. See webinar connection details here.

 

Join the CIBRN Leaders for a webinar on Wednesday, May 22, 9:00 pm ET.

Please join the CIBRN Leaders for Webinar 1 of 2019 on Wednesday, May 22 at 9:00 pm ET. The webinar will review the recent discussions and podcast in the CIBRN community:

  • CIBRN 2019 Q1: Should drug approvals be based on efficacy and demonstrated need, or should pharmacoeconomics be a larger consideration? [View 5 replies to date]
  • CIBRN 2019 Q2: Should manufacturers’ rebates be kept confidential, or should full transparency be expected, in order to more properly compare costs between originators and biosimilars? [View 4 replies to date]
  • CIBRN Podcast Episode 1: Dr. Philip Baer on “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18) [Listen to the podcast]

To connect to the webinar:

Step 1: Join the teleconference at 1-866-830-9434 and enter PIN 7994216

Step 2: Join the web portion by clicking on this link:
https://studio7communications.adobeconnect.com/cibrn_may22_2019/

Listen to CIBRN Podcast Episode 1: Dr. Philip Baer reviews “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18)

Welcome to the CIBRN Podcast channel. This year, we’ve decided to take a fresh approach to article reviews, providing timely and brief (3-5 minutes) podcasts on articles selected and reviewed by CIBRN members. The first in the series has been provided by Dr. Philip Baer.

CIBRN Podcast Episode 1: Dr. Philip Baer on “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18)

Link to reviewed article

Now Available Online: Archived recording of CIBRN virtual review webinar #4 led by Dr. Mark Kirchhof

We invite you to view the archived recording of the virtual review webinar which was held on October 18, 2018, led by Dr. Mark Kirchhof featuring the recent article in the British Journal of Dermatology by Blauvelt et al: Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

NOTE: If you would like a full-text copy of the article above, please contact paul.abbass@legitimed.com

Click to view video: http://bit.ly/2ywVSj9

Now Available Online: Archived recording of CIBRN virtual review webinar #3 led by Dr. Gordon Searles

We invite you to view the archived recording of the virtual review webinar which was held on September 20th, led by Dr. Gordon Searles featuring the recent article in Advances in Therapy by Numan et al: Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies [link to full text]

Click to view video: http://bit.ly/2OGSfk2

Join Dr. Mark Kirchhof Oct 18, 8pm ET for virtual review of “Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches” (Blauvelt et al, Br J Dermatol, Jun 2018).

Please join Dr. Mark Kirchhof for WEBINAR 4 of 2018 to be held Thursday, October 18 at 8pm EST, focused on the recent article in the British Journal of Dermatology by Blauvelt et al:

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

NOTE: If you would like a full-text copy of the article above, please contact paul.abbass@legitimed.com

For webinar access details, see calendar invitation.

If you have any comments or questions, please contact:

Paul Abbass
LEGITIMED INC.
paul.abbass@legitimed.com

Join Dr. Gordon Searles Sep 20, 8pm ET for virtual review of “Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies” (Numan et al, Adv Ther, Sep 2018).

Please join Dr. Gordon Searles for WEBINAR 3 of 2018 to be held Thursday, September 20 at 8pm EST, focused on the recent article in Advances in Therapy by Numan et al:

Link to full text article: Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies

For webinar access details, see calendar invitation.

If you have any comments or questions, please contact:

Paul Abbass
LEGITIMED INC.
paul.abbass@legitimed.com